215 related articles for article (PubMed ID: 31366602)
1. Evaluation of Factor VIII Polysialylation: Identification of a Longer-Acting Experimental Therapy in Mice and Monkeys.
Glantschnig H; Bauer A; Benamara K; Dockal M; Ehrlich V; Gritsch H; Höbarth G; Horling FM; Kopic A; Leidenmühler P; Reipert BM; Rottensteiner H; Ruthsatz T; Schrenk G; Schuster M; Turecek PL; Weber A; Wolfsegger M; Scheiflinger F; Höllriegl W
J Pharmacol Exp Ther; 2019 Oct; 371(1):95-105. PubMed ID: 31366602
[TBL] [Abstract][Full Text] [Related]
2. Impact of capacity-limited binding on recombinant factor VIII and von Willebrand factor pharmacokinetics in hemophilia A rats.
Vargas Christensen I; Loftager M; Rode F; Mørck Nielsen H; Kreilgaard M; Larsen MS
J Thromb Haemost; 2019 Jun; 17(6):964-974. PubMed ID: 30924607
[TBL] [Abstract][Full Text] [Related]
3. SHP656, a polysialylated recombinant factor VIII (PSA-rFVIII): First-in-human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A.
Tiede A; Allen G; Bauer A; Chowdary P; Collins P; Goldstein B; Jiang HJ; Kӧck K; Takács I; Timofeeva M; Wolfsegger M; Srivastava S
Haemophilia; 2020 Jan; 26(1):47-55. PubMed ID: 31778283
[TBL] [Abstract][Full Text] [Related]
4. Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis.
Miners AH; Krishnan S; Pasi KJ
J Thromb Haemost; 2016 Nov; 14(11):2141-2147. PubMed ID: 27510890
[TBL] [Abstract][Full Text] [Related]
5. Efmoroctocog Alfa: A Review in Haemophilia A.
Frampton JE
Drugs; 2021 Nov; 81(17):2035-2046. PubMed ID: 34743314
[TBL] [Abstract][Full Text] [Related]
6. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
Shah A; Coyle T; Lalezari S; Fischer K; Kohlstaedde B; Delesen H; Radke S; Michaels LA
Haemophilia; 2018 Sep; 24(5):733-740. PubMed ID: 29963724
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII.
Hermans C; Mahlangu J; Booth J; Schütz H; Santagostino E; Young G; Lee HY; Steinitz-Trost KN; Blanchette V; Berntorp E
Haemophilia; 2018 May; 24(3):376-384. PubMed ID: 29732708
[TBL] [Abstract][Full Text] [Related]
8. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.
Powell JS; Josephson NC; Quon D; Ragni MV; Cheng G; Li E; Jiang H; Li L; Dumont JA; Goyal J; Zhang X; Sommer J; McCue J; Barbetti M; Luk A; Pierce GF
Blood; 2012 Mar; 119(13):3031-7. PubMed ID: 22223821
[TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model.
Rode F; Almholt K; Petersen M; Kreilgaard M; Kjalke M; Karpf DM; Groth AV; Johansen PB; Larsen LF; Loftager M; Haaning J
J Thromb Haemost; 2018 Jun; 16(6):1141-1152. PubMed ID: 29582559
[TBL] [Abstract][Full Text] [Related]
10. Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS.
Lalezari S; Martinowitz U; Windyga J; Enriquez MM; Delesen H; Schwartz L; Scharrer I
Haemophilia; 2014 Jan; 20(1):e15-22. PubMed ID: 24252058
[TBL] [Abstract][Full Text] [Related]
11. Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII.
Zollner S; Raquet E; Claar P; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
Thromb Res; 2014 Jul; 134(1):125-31. PubMed ID: 24814969
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations.
Bukkems LH; Preijers T; van Spengler MWF; Leebeek FWG; Cnossen MH; Mathôt RAA
Thromb Haemost; 2021 Jun; 121(6):731-740. PubMed ID: 33506481
[TBL] [Abstract][Full Text] [Related]
13. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.
Zollner SB; Raquet E; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
Thromb Res; 2013 Aug; 132(2):280-7. PubMed ID: 23830969
[TBL] [Abstract][Full Text] [Related]
14. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.
Pipe SW; Montgomery RR; Pratt KP; Lenting PJ; Lillicrap D
Blood; 2016 Oct; 128(16):2007-2016. PubMed ID: 27587878
[TBL] [Abstract][Full Text] [Related]
15. Recombinant factor VIII: past, present and future of treatment of hemophilia A.
Raso S; Hermans C
Drugs Today (Barc); 2018 Apr; 54(4):269-281. PubMed ID: 29869648
[TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
Carcao MD; Chelle P; Clarke E; Kim L; Tiseo L; Morfini M; Hossain T; Rand ML; Brown C; Edginton AN; Lillicrap D; Iorio A; Blanchette VS
J Thromb Haemost; 2019 Jul; 17(7):1085-1096. PubMed ID: 31038793
[TBL] [Abstract][Full Text] [Related]
17. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States.
Neufeld EJ; Sidonio RF; O'Day K; Runken MC; Meyer K; Spears J
J Med Econ; 2018 Aug; 21(8):762-769. PubMed ID: 29681200
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis--a meta-analysis.
Gruppo RA; Brown D; Wilkes MM; Navickis RJ
Haemophilia; 2003 May; 9(3):251-60. PubMed ID: 12694514
[TBL] [Abstract][Full Text] [Related]
19. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.
Seth Chhabra E; Liu T; Kulman J; Patarroyo-White S; Yang B; Lu Q; Drager D; Moore N; Liu J; Holthaus AM; Sommer JM; Ismail A; Rabinovich D; Liu Z; van der Flier A; Goodman A; Furcht C; Tie M; Carlage T; Mauldin R; Dobrowsky TM; Liu Z; Mercury O; Zhu L; Mei B; Schellenberger V; Jiang H; Pierce GF; Salas J; Peters R
Blood; 2020 Apr; 135(17):1484-1496. PubMed ID: 32078672
[TBL] [Abstract][Full Text] [Related]
20. Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice.
Vollack-Hesse N; Oleshko O; Werwitzke S; Solecka-Witulska B; Kannicht C; Tiede A
Blood; 2021 Feb; 137(8):1072-1081. PubMed ID: 32877516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
